echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The 1.1 class of anti Alzheimer's candidate drug GIBH130 has been approved by clinical trial.

    The 1.1 class of anti Alzheimer's candidate drug GIBH130 has been approved by clinical trial.

    • Last Update: 2016-04-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Comparison of brain hippocampal slices of disease model mice: oral administration of gibh-130 can protect neurons According to the Chinese Academy of Sciences, gibh-130 and its tablets, a new anti Alzheimer's drug, have obtained the "approval for clinical trials of drugs" issued by the State Food and drug administration This achievement was designed and synthesized by Hu Wenhui research group of Guangzhou Institute of biomedicine and health, Chinese Academy of Sciences, and pre clinical research was led by South China new drug creation center Alzheimer's disease, commonly known as Alzheimer's disease, is a degenerative disease of the central nervous system, which leads to cognitive impairment and memory impairment of patients, leading to the deterioration of living ability and death of patients According to data from the international Alzheimer's Federation, in 2013, the number of patients worldwide totaled 44.35 million; by 2030, it will increase to 75.62 million; by 2050, it will increase to 135.46 million, including 30 million in China As the pathogenesis is still unclear, there is a lack of effective treatment and prevention measures "The main clinical drugs are cholinesterase inhibitors (Achei) and N-methyl-D-aspartate (NMDA) receptor antagonists." Hu said that these drugs can only alleviate symptoms to a certain extent, improve patients' cognitive ability, and can not cure the disease or delay the progression of the disease Hu Wenhui's research group began to construct a centralized compound library of neuroinflammatory inhibitors in 2006, and in 2008, gibh130, an anti neuroinflammatory inhibitor with the potential of proprietary drugs, was obtained Gibh130 has been confirmed by other biological teams to have good anti-inflammatory effect in vitro, good oral utilization, easy to penetrate the blood-brain barrier, and superior efficacy in multiple animal models of Alzheimer's disease In 2012, the Guangzhou Academy of biological sciences of the Chinese Academy of Sciences (CAS) and the Southern China new drug discovery center (CDC) Co operated with each other to carry out pre clinical studies on "1.1 kinds of anti Alzheimer's disease drug candidate GIBH130" After completing all preclinical studies, they applied for clinical studies of new drugs As a new structure of neuroinflammatory inhibitor, gibh130 can block the over activation of glial cells, inhibit the increase of inflammatory factors in the brain, reduce the damage of neurons, and thus block the process of disease, Hu said It also has the characteristics of high activity, high bioavailability, good safety, easy access to raw materials and simple process, especially the low dosage It is expected that patients only need to take orally once a day (dosage 1-10mg) According to Hu, gibh130 has applied for patents in many countries and regions, and has been authorized by the United States, Japan and Germany He hoped that the drug would be listed successfully and become "a good drug for the common people in China"  
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.